Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based

Hop S Tran Cao1, Nicole Lopez2, David C Chang2

  • 1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston2Department of Surgery, UC San Diego Health System, University of California, San Diego.

JAMA Surgery
|January 10, 2014
PubMed
Abstract

Insights

Minimally invasive distal pancreatectomy (MIDP) use tripled from 1998-2009. MIDP is a safe option, showing fewer complications and shorter stays than open surgery, with similar mortality and costs.

Area of Science:

  • Surgical Oncology
  • Gastroenterology
  • Health Services Research

Background:

  • Minimally invasive distal pancreatectomy (MIDP) interest is growing, but data are limited.
  • National database inquiry can provide insight into MIDP application and outcomes.

Purpose of the Study:

  • To examine trends in MIDP utilization.
  • To compare short-term outcomes of MIDP versus open distal pancreatectomy.

Main Methods:

  • Population-based retrospective cohort study (1998-2009).
  • Utilized Nationwide Inpatient Sample (20% stratified sample).
  • Compared perioperative outcomes and hospital charges for MIDP and open distal pancreatectomy, adjusting for patient and hospital factors.

Main Results:

  • MIDP use tripled between 1998 and 2009 (2.4% to 7.3%).
  • MIDP associated with lower overall predischarge complications (infections, bleeding) and shorter length of stay (1.22 days).
  • No significant differences in in-hospital mortality, splenectomy rates, or total charges.

Conclusions:

  • MIDP application has tripled, indicating increased adoption.
  • MIDP is a safe and effective surgical option for pancreatic diseases.
  • Evidence supports MIDP as a viable alternative to open surgery.